# Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-h-1adfec22
Ticker: KROS
Company: Keros Therapeutics
Source: Keros Therapeutics
Published: 2026-06-01 20:01 EST
## Summary

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

## Article Body
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://cc.webcasts.com/gold006/060826a_js/?entity=146_YVQJ8LJ and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Investor Contact: Justin Frantz jfrantz@kerostx.com 617-221-6042
## Recent Company News
- 2026-06-25 20:01 EST — [Keros Therapeutics Appoints Anne Prener to its Board of Directors](https://biopharmsignal.com/news/KROS/keros-therapeutics-appoints-anne-prener-to-its-board-of-directors-7c27ad3b) — Source: Keros Therapeutics
- 2026-06-01 20:01 EST — [Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-h-1adfec22) — Source: Keros Therapeutics
- 2026-05-14 12:00 EST — [Keros Therapeutics Reports Recent First Quarter 2026 Financial Results](https://biopharmsignal.com/news/KROS/keros-therapeutics-reports-recent-first-quarter-2026-financial-results-632f1ff6) — Source: Keros Therapeutics
- 2026-03-09 12:00 EST — [Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS](https://biopharmsignal.com/news/KROS/keros-therapeutics-announces-collaboration-with-sean-m-healey-amg-center-for-als-d15ac672) — Source: Keros Therapeutics
- 2026-03-09 12:00 EST — [Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference](https://biopharmsignal.com/news/KROS/keros-therapeutics-presents-additional-clinical-data-from-its-rinvatercept-progr-c434ac4c) — Source: Keros Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)